

MEDIA RELEASE

18 July 2022

ARTRYA MEDICAL ADVISOR AWARDED BEST ABSTRACT AT SOCIETY OF CARDIOVASCULAR COMPUTED TOMOGRAPHY MEETING

Perth, Western Australia., (18 July, 2022) – Artrya Medical Advisor, Perth-based cardiologist Dr Abdul Rahman Ihdahid, has been awarded the Best Abstract Award in cardiovascular computed tomography at the closing ceremony of the 2022 Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Las Vegas overnight.

The submission titled 'Comprehensive assessment of coronary artery disease on CCTA using deep learning methods' evaluated the feasibility and accuracy of a novel artificial intelligence algorithm developed by Artrya for identifying within minutes coronary artery blockages and coronary plaque that increase the risk of heart attack.

The innovative algorithms were tested and validated by Dr Ihdahid and his team based at Harry Perkins Institute of Medical Research and Fiona Stanley Hospital. The high accuracy results highlight the opportunity of artificial intelligence to improve the diagnosis of coronary artery disease.

Artrya Chief Scientific Officer, Professor Girish Dwivedi, MD, congratulated Dr Ihdahid and the Artrya team for their exceptional work.

"This winning submission helps to improve our understanding of how technological advances and analysis of plaque morphology and composition can allow patients a more personalised approach to cardiac assessment. Artificial intelligence and deep learning methods can help to optimise image acquisition, analysis, and diagnostic accuracy," said Professor Dwivedi.

The SCCT Best Abstract Award, supported by the Cardiovascular Research Foundation of Southern California - Ma Family, aims to help strengthen the professional and clinical development of top radiology residents and cardiology fellows.

Dr Ihdahid was one of seven finalists who gave an oral presentation of their abstract submission before an independent panel of judges. The award was presented by a Ma family representative and incoming SCCT President, Mr Brian Ghoshhajra, MD.

Artrya's core solution is the novel technology Salix – a fast and effective AI-based solution that analyses cardiac CT scans to detect a unique combination of heart attack biomarkers. Salix supports clinicians in the diagnosis of coronary artery disease by highlighting disease location and severity on a 3D heart image and producing a comprehensive patient report within 15 minutes, assisting first-time-right treatment.

...1/2

About Dr Abdul Rahman Ihdahid

Dr Ihdahid is a cardiologist with a consultant appointment at Fiona Stanley Hospital and academic affiliation with Harry Perkins Institute of Medical Research and Curtin Medical School. As a leader in coronary artery disease diagnosis and treatment, Dr. Ihdahid uses his practical and academic knowledge to inform Artrya's research and development, including testing and validating product accuracy and efficacy. He also assists with clinical education and awareness and is a key opinion leader on the benefits of early, non-invasive coronary artery disease diagnosis.

About Artrya

Based in Perth, Western Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA). Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary artery disease and develop a holistic overview of a patient at risk. Artrya has developed deep learning algorithms that will streamline how medical care for heart disease is delivered.

Artrya USA Inc. is a wholly owned subsidiary of Artrya Limited.

For more information: www.artrya.com

For media enquires please contact:

Felicity Heath

Daymark

+61 457 196 603

felicity.heath@daymark.com.au

-Ends-